<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://www.biopharmawatch.com/news/AVR/anteris-duravr-thv-1-year-outcomes</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-22T10:24:00.000Z</news:publication_date>
      <news:title>Anteris’ DurAVR THV Demonstrates 1% Heart Failure Hospitalization, Single-Digit Gradients and No Valve-Related Deaths at 1 Year in Patients with Small Aortic Annuli</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-provides-regulatory-update-deramiocel-bla-duchenne-muscular</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-21T00:55:00.000Z</news:publication_date>
      <news:title>Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MRM/medirom-regains-compliance-nasdaq-filing-requirement</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T23:42:00.000Z</news:publication_date>
      <news:title>MEDIROM Regains Compliance with Nasdaq’s Periodic Filing Requirement</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SGRY/surgery-partners-consent-solicitation-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T22:49:00.000Z</news:publication_date>
      <news:title>Surgery Partners, Inc. Announces Expiration and Results of Consent Solicitation Relating to Surgery Center Holdings, Inc.’s 7.250% Senior Notes due 2032</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ALPS/alps-group-regains-nasdaq-compliance</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T22:15:00.000Z</news:publication_date>
      <news:title>Alps Group Inc Regains Compliance with Nasdaq Minimum Bid Price Requirement</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261120</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T22:15:00.000Z</news:publication_date>
      <news:title>Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BCLI/brainstorm-cell-settlement-notice-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T22:00:00.000Z</news:publication_date>
      <news:title>Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Matters</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TOVX/theriva-biologics-reverse-stock-split</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:35:00.000Z</news:publication_date>
      <news:title>Theriva™ Biologics Announces Reverse Stock Split</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ABVX/abivax-statement-short-seller-report</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:33:00.000Z</news:publication_date>
      <news:title>Abivax Statement on Short Seller Report</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MTD/mettlertoledo-present-evercore-healthcare-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:30:00.000Z</news:publication_date>
      <news:title>Mettler-Toledo International Inc. to Present at Upcoming Investor Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TEVA/teva-presents-at-upcoming-healthcare-conferences</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:30:00.000Z</news:publication_date>
      <news:title>Teva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi’s 2026 Global Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RLYB/avenzo-therapeutics-merger-rallybio</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:30:00.000Z</news:publication_date>
      <news:title>Avenzo Therapeutics Announces Closing of Merger with Rallybio Corporation and Previously Announced $215 Million Concurrent Private Placement</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BON/bon-joint-lab-natural-ingredients-biomanufacturing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:30:00.000Z</news:publication_date>
      <news:title>BON Unveils Joint Lab for Natural Ingredients &amp; Biomanufacturing with China Oat Group, Advancing Life Sciences Innovation</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-inducement-grants-nasdaq-5635c4</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:05:00.000Z</news:publication_date>
      <news:title>Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NSPR/inspiremd-announces-inducement-grants-nasdaq-listing-rule-5635-c-4-20261120</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:05:00.000Z</news:publication_date>
      <news:title>InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-evercore-healthcare-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:04:00.000Z</news:publication_date>
      <news:title>AN2 Therapeutics to Participate in 9th Annual Evercore Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CDNA/caredx-participate-investor-conferences</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:01:00.000Z</news:publication_date>
      <news:title>CareDx to Participate in Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-public-offering-172-million</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:01:00.000Z</news:publication_date>
      <news:title>SELLAS Life Sciences Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-kt-621-broadens-phase-2b-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:01:00.000Z</news:publication_date>
      <news:title>Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-announces-inducement-grants-new-employees-nasdaq-listing-rule</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T21:00:00.000Z</news:publication_date>
      <news:title>Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/XCUR/exicure-expands-parkinsons-disease-market</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T18:00:00.000Z</news:publication_date>
      <news:title>Exicure Announces Strategic Expansion into Parkinson’s Disease</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SRXH/srx-global-engineered-t-cell-strategy-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T17:58:00.000Z</news:publication_date>
      <news:title>SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing Agreement</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-pynnacle-phase-2-trial-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T15:30:00.000Z</news:publication_date>
      <news:title>PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GSK/gsk-transfer-treasury-shares</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T15:25:38.000Z</news:publication_date>
      <news:title>Transfer of Treasury Shares</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MMM/3m-announces-upcoming-investor-event-20261120</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T15:15:00.000Z</news:publication_date>
      <news:title>3M Announces Upcoming Investor Event</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CVS/cvs-home-team-heroes-soccer-contest-winners</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T14:40:00.000Z</news:publication_date>
      <news:title>CVS Pharmacy® names Grand Prize winners of first Home Team Heroes youth soccer contest</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IMCC/im-cannabis-new-ceo-ronen-zalayet</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T14:19:00.000Z</news:publication_date>
      <news:title>IM Cannabis Corp. Appoints New CEO to Lead Technology-Driven Business Expansion</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PPBT/purple-biotech-im1240-eortc-nci-aacr-symposium</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T14:00:00.000Z</news:publication_date>
      <news:title>Purple Biotech&apos;s IM1240, a CAPTN-3-Capped Tri-Specific T- and NK-Cell Engager Targeting 5T4, Shows Robust Tumor Killing in Immunotherapy-Resistant Cancer Models in Plenary Oral Presentation at EORTC-NCI-AACR Symposium</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/JAGX/jaguar-health-reverse-stock-split-november-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T14:00:00.000Z</news:publication_date>
      <news:title>Jaguar Health, Inc. Announces Reverse Stock Split</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GEHC/ge-healthcare-imaging-360-ai-features</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T14:00:00.000Z</news:publication_date>
      <news:title>GE HealthCare introduces new Imaging 360 features to simplify protocol management and support radiology workflows</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-phase-1-results-apr-1051</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T14:00:00.000Z</news:publication_date>
      <news:title>Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NVNO/envveno-medical-three-year-data-veith-symposium</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:41:00.000Z</news:publication_date>
      <news:title>enVVeno Medical Presents Three-Year Surgical Venous Valve Replacement Data Showing Sustained Clinical Benefit and Highlights Next-Generation enVVe Transcatheter System at the 53rd Annual VEITH Symposium</news:title>
    </news:news>
  </url>
</urlset>